Hazard Ratios (HRs) of Study End Points for Plasma Levels of Interleukin 6 (IL-6), High-Sensitivity C-Reactive Protein (hsCRP), and D-Dimer
| End Point . | IL-6, HR (95% CI) . | hsCRP, HR (95% CI) . | D-Dimer, HR (95% CI) . | |||
|---|---|---|---|---|---|---|
| 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | |
| All-cause death | 1.64 (1.41–1.92) | 3.07 (1.70–5.55) | 1.29 (1.17–1.42) | 2.73 (1.56–4.69) | 1.32 (1.14–1.52) | 3.00 (1.61–5.59) |
| Non–AIDS-related, nonviolent, unintentional death | 1.77 (1.50–2.10) | 6.31 (2.68–14.83) | 1.30 (1.16–1.46) | 3.10 (1.59–6.05) | 1.30 (1.10–1.53) | 3.38 (1.62–7.08) |
| Progression to AIDS | 1.32 (1.07–1.62) | 1.63 (.83–3.21) | 1.07 (.94–1.21) | 1.35 (.74–2.48) | 1.35 (1.12–1.63) | 2.20 (1.07–4.50) |
| Cardiovascular disease event | 1.40 (1.17–1.67) | 3.34 (1.66–6.70) | 1.11 (.99–1.24) | 1.89 (.99–3.63) | 1.22 (1.04–1.43) | 1.80 (.98–3.29) |
| Non–AIDS-defining malignancy | 1.31 (1.07–1.61) | 3.12 (1.42–6.84) | 1.16 (1.02–1.32) | 1.68 (.86–3.28) | 1.09 (.91–1.31) | 1.03 (.55–1.94) |
| End Point . | IL-6, HR (95% CI) . | hsCRP, HR (95% CI) . | D-Dimer, HR (95% CI) . | |||
|---|---|---|---|---|---|---|
| 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | |
| All-cause death | 1.64 (1.41–1.92) | 3.07 (1.70–5.55) | 1.29 (1.17–1.42) | 2.73 (1.56–4.69) | 1.32 (1.14–1.52) | 3.00 (1.61–5.59) |
| Non–AIDS-related, nonviolent, unintentional death | 1.77 (1.50–2.10) | 6.31 (2.68–14.83) | 1.30 (1.16–1.46) | 3.10 (1.59–6.05) | 1.30 (1.10–1.53) | 3.38 (1.62–7.08) |
| Progression to AIDS | 1.32 (1.07–1.62) | 1.63 (.83–3.21) | 1.07 (.94–1.21) | 1.35 (.74–2.48) | 1.35 (1.12–1.63) | 2.20 (1.07–4.50) |
| Cardiovascular disease event | 1.40 (1.17–1.67) | 3.34 (1.66–6.70) | 1.11 (.99–1.24) | 1.89 (.99–3.63) | 1.22 (1.04–1.43) | 1.80 (.98–3.29) |
| Non–AIDS-defining malignancy | 1.31 (1.07–1.61) | 3.12 (1.42–6.84) | 1.16 (1.02–1.32) | 1.68 (.86–3.28) | 1.09 (.91–1.31) | 1.03 (.55–1.94) |
HRs were adjusted for demographic characteristics (age, sex, race, and body mass index [calculated as the weight in kilograms divided by the height in meters squared]), nadir and baseline CD4+ T-cell counts, antiretroviral therapy use, baseline human immunodeficiency virus RNA level, prior AIDS and cardiovascular disease, diabetes mellitus, and hepatitis B virus and hepatitis C virus coinfection, stratified by study (model 2). For detailed information on results using models 1 and 3, refer to Supplementary Tables 1 and 2.
Abbreviation: CI, confidence interval.
Hazard Ratios (HRs) of Study End Points for Plasma Levels of Interleukin 6 (IL-6), High-Sensitivity C-Reactive Protein (hsCRP), and D-Dimer
| End Point . | IL-6, HR (95% CI) . | hsCRP, HR (95% CI) . | D-Dimer, HR (95% CI) . | |||
|---|---|---|---|---|---|---|
| 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | |
| All-cause death | 1.64 (1.41–1.92) | 3.07 (1.70–5.55) | 1.29 (1.17–1.42) | 2.73 (1.56–4.69) | 1.32 (1.14–1.52) | 3.00 (1.61–5.59) |
| Non–AIDS-related, nonviolent, unintentional death | 1.77 (1.50–2.10) | 6.31 (2.68–14.83) | 1.30 (1.16–1.46) | 3.10 (1.59–6.05) | 1.30 (1.10–1.53) | 3.38 (1.62–7.08) |
| Progression to AIDS | 1.32 (1.07–1.62) | 1.63 (.83–3.21) | 1.07 (.94–1.21) | 1.35 (.74–2.48) | 1.35 (1.12–1.63) | 2.20 (1.07–4.50) |
| Cardiovascular disease event | 1.40 (1.17–1.67) | 3.34 (1.66–6.70) | 1.11 (.99–1.24) | 1.89 (.99–3.63) | 1.22 (1.04–1.43) | 1.80 (.98–3.29) |
| Non–AIDS-defining malignancy | 1.31 (1.07–1.61) | 3.12 (1.42–6.84) | 1.16 (1.02–1.32) | 1.68 (.86–3.28) | 1.09 (.91–1.31) | 1.03 (.55–1.94) |
| End Point . | IL-6, HR (95% CI) . | hsCRP, HR (95% CI) . | D-Dimer, HR (95% CI) . | |||
|---|---|---|---|---|---|---|
| 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | 2-Fold Higher Level . | 4th/1st Quartile . | |
| All-cause death | 1.64 (1.41–1.92) | 3.07 (1.70–5.55) | 1.29 (1.17–1.42) | 2.73 (1.56–4.69) | 1.32 (1.14–1.52) | 3.00 (1.61–5.59) |
| Non–AIDS-related, nonviolent, unintentional death | 1.77 (1.50–2.10) | 6.31 (2.68–14.83) | 1.30 (1.16–1.46) | 3.10 (1.59–6.05) | 1.30 (1.10–1.53) | 3.38 (1.62–7.08) |
| Progression to AIDS | 1.32 (1.07–1.62) | 1.63 (.83–3.21) | 1.07 (.94–1.21) | 1.35 (.74–2.48) | 1.35 (1.12–1.63) | 2.20 (1.07–4.50) |
| Cardiovascular disease event | 1.40 (1.17–1.67) | 3.34 (1.66–6.70) | 1.11 (.99–1.24) | 1.89 (.99–3.63) | 1.22 (1.04–1.43) | 1.80 (.98–3.29) |
| Non–AIDS-defining malignancy | 1.31 (1.07–1.61) | 3.12 (1.42–6.84) | 1.16 (1.02–1.32) | 1.68 (.86–3.28) | 1.09 (.91–1.31) | 1.03 (.55–1.94) |
HRs were adjusted for demographic characteristics (age, sex, race, and body mass index [calculated as the weight in kilograms divided by the height in meters squared]), nadir and baseline CD4+ T-cell counts, antiretroviral therapy use, baseline human immunodeficiency virus RNA level, prior AIDS and cardiovascular disease, diabetes mellitus, and hepatitis B virus and hepatitis C virus coinfection, stratified by study (model 2). For detailed information on results using models 1 and 3, refer to Supplementary Tables 1 and 2.
Abbreviation: CI, confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
